文献速递技术与安全CTDSA

非离子型碘对比剂急性不良反应:一项Meta分析

Acute Adverse Reactions to Nonionic Iodinated Contrast Media: A Meta-Analysis.
PubMed 文献 · Invest Radiol · 2019-01-01

该系统评价与Meta分析纳入30项研究、共1,360,488次非离子型碘对比剂血管内给药暴露,汇总急性不良反应总发生率为1.03%、严重急性不良反应为0.0141%。多因素Meta回归显示研究设计和预用药是总急性不良反应发生率的显著决定因素,而对比剂类型对总急性及严重急性不良反应发生率均无显著影响。作者认为结果可能支持在避免急性不良反应的背景下不限制特定类型非离子型碘对比剂。

要点

  • 非离子型碘对比剂总急性不良反应汇总发生率为1.03%(95%CI 0.81%-1.30%)。
  • 严重急性不良反应汇总发生率为0.0141%(95%CI 0.0108%-0.0183%)。
  • 多因素Meta回归显示对比剂类型对总急性及严重急性不良反应发生率均无显著影响(P=0.1453和0.4265)。

核心结论

  • 调整混杂因素后,特定类型非离子型碘对比剂之间总急性及严重急性不良反应的汇总发生率差异不再显著。

研究设计与样本

  • 系统评价与Meta分析,纳入30项研究、共1,360,488次非离子型碘对比剂血管内给药暴露,评估7种非离子型碘对比剂(碘比醇、碘海醇、碘美普尔、碘帕醇、碘普罗胺、碘佛醇和碘克沙醇)的急性不良反应发生率,采用随机效应模型汇总,并用Meta回归分析对比剂类型对总急性及严重急性不良反应发生率的影响。

诊断标准与关键数值

  • 非离子型碘对比剂总急性不良反应汇总发生率为1.03%(95%CI 0.81%-1.30%)。
  • 非离子型碘对比剂严重急性不良反应汇总发生率为0.0141%(95%CI 0.0108%-0.0183%)。
  • 碘美普尔总急性不良反应发生率最高,为1.74%(95%CI 0.79%-3.76%),其次为碘海醇1.21%(95%CI 0.67%-2.17%)、碘帕醇1.10%(95%CI 0.60%-2.03%)、碘佛醇0.88%(95%CI 0.43%-1.83%)、碘克沙醇0.85%(95%CI 0.36%-1.95%)、碘普罗胺0.82%(95%CI 0.43%-1.55%)、碘比醇0.77%(95%CI 0.36%-1.62%)。
  • 多因素Meta回归分析显示研究设计(P=0.0014)和预用药(P=0.0230)是影响总急性不良反应发生率的显著决定因素。
  • 对比剂类型不影响总急性及严重急性不良反应发生率(P=0.1453和0.4265)。

临床应用与阅片要点

  • 作者认为结果可能支持在避免急性不良反应的背景下不限制特定类型非离子型碘对比剂。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: We aimed to meta-analytically compare the incidence of acute adverse reactions (AARs) to nonionic iodinated contrast media (ICM) according to the type of ICM in patients who underwent radiologic examinations with administration of ICM via intravascular route.

MATERIALS AND METHODS: A systematic literature search identified studies evaluating the incidence of AARs to 7 nonionic ICM (iobitridol, iohexol, iomeprol, iopamidol, iopromide, ioversol, and iodixanol) with extractable outcomes. These outcomes were pooled using a random-effects model, and the effect of ICM type on the incidence of overall and severe AARs was evaluated using meta-regression analysis.

RESULTS: Thirty studies with 1,360,488 exposures to ICM were included. The pooled incidences of overall and severe AARs to nonionic ICM were 1.03% (95% confidence interval [CI], 0.81%-1.30%; I = 0.99) and 0.0141% (95% CI, 0.0108%-0.0183%; I = 0.56), respectively. Iomeprol had the highest overall AAR incidence (1.74%; 95% CI, 0.79%-3.76%; I = 0.99), followed by iohexol (1.21%; 95% CI, 0.67%-2.17%; I = 0.99), iopamidol (1.10%; 95% CI, 0.60%-2.03%; I = 0.99), ioversol (0.88%; 95% CI, 0.43%-1.83%; I = 0.96), iodixanol (0.85%; 95% CI, 0.36%-1.95%; I = 0.99), iopromide (0.82%; 95% CI, 0.43%-1.55%; I = 0.99), and iobitridol (0.77%; 95% CI, 0.36%-1.62%; I = 0.99). Multivariable meta-regression analysis revealed that study design (P = 0.0014) and premedication (P = 0.0230) were statistically significant determinants affecting the incidence of overall AARs. Iodinated contrast media type did not affect the incidence of overall and severe AARs (P = 0.1453 and 0.4265, each).

CONCLUSIONS: The varying pooled incidences of overall and severe AARs to specific types of nonionic ICM do not remain as significant after adjusting confounders. Our results may support nonrestriction of certain types of nonionic ICM in the context of AAR avoidance.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Suh YJ, Yoon SH, Hong H, et al. Acute Adverse Reactions to Nonionic Iodinated Contrast Media: A Meta-Analysis. Invest Radiol. 2019. PMID: 30998567. doi:10.1097/RLI.0000000000000568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。